U.S. Specialized REITs Stock News

NYSE:EHC
NYSE:EHCHealthcare

Encompass Health (EHC) Is Up 12.7% After Raising 2026 Guidance And Completing Major Buyback Program – Has The Bull Case Changed?

Encompass Health reported past second-quarter 2026 results with net operating revenue of US$1,597.4 million and net income of US$153.9 million, alongside higher earnings per share versus a year earlier. The company also raised its full-year 2026 revenue guidance and completed a long-running share repurchase program that has retired nearly one-tenth of its shares. We’ll now examine how Encompass Health’s raised 2026 revenue guidance shapes its investment narrative and what it may mean for...
NasdaqCM:PRCH
NasdaqCM:PRCHInsurance

Porch Group (PRCH) Is Up 9.7% After Strong Q2 Profit, 2026 Upgrade and ESOP Shelf Filing

In late July 2026, Porch Group, Inc. reported second-quarter sales of US$140.88 million and net income of US$5.6 million, alongside filing a US$28.428 million shelf registration for 2,300,000 common shares tied to an ESOP-related offering. The combination of stronger quarterly profitability, higher full-year guidance and an ESOP-linked shelf filing highlights how Porch is pairing operational progress with added flexibility in its capital structure and employee incentives. With Porch...
NasdaqGS:SWKS
NasdaqGS:SWKSSemiconductor

Skyworks Solutions (SWKS) Buyback And Dividend Shift Put Valuation Back In Focus

Skyworks Solutions (SWKS) is back in focus after Q3 FY2026 results showed year over year pressure on revenue and net income, alongside a decision to halt quarterly dividends and launch a new US$2b share repurchase plan. See our latest analysis for Skyworks Solutions. Skyworks Solutions shares have reacted strongly to the latest update, with a 1 day share price return of 5.66% and a 30 day share price return of 20.74%. The 1 year total shareholder return of 3.53% sits against a 3 year total...
NasdaqGM:PVLA
NasdaqGM:PVLABiotechs

Palvella Therapeutics (PVLA) Earnings And QTORIN Hopes Keep Undervaluation In Focus

Palvella Therapeutics earnings and new shelf filing set the tone Palvella Therapeutics (PVLA) reported second quarter 2026 results on 4 August, with net loss and loss per share both wider than a year earlier. The company also filed a new shelf registration tied to an ESOP related offering. See our latest analysis for Palvella Therapeutics. The earnings release and new ESOP related shelf registration came alongside very strong momentum in Palvella Therapeutics' stock. The latest close at...